Lifesci Capital Has Negative Estimate for TARS Q2 Earnings

Key Points

• Lifesci Capital cut its Q2 2026 EPS estimate for Tarsus Pharmaceuticals to -$0.36 from -$0.13, even while maintaining a Strong Buy rating on the stock.
• Tarsus just reported Q1 results that beat expectations, posting EPS of -$0.16 versus -$0.40 expected and revenue of $162.05 million versus $149.60 million consensus.
• Despite some bullish analyst views and strong recent sales growth, several firms trimmed near-term estimates, reflecting continued losses in the near term even as the company’s XDEMVY franchise remains strong.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Equities researchers at Lifesci Capital lowered their Q2 2026 earnings estimates for shares of Tarsus Pharmaceuticals in a report issued on Thursday, May 7th. Lifesci Capital analyst F. Brisebois now forecasts that the company will post earnings per share of ($0.36) for the quarter, down from their previous forecast of ($0.13). Lifesci Capital has a "Strong-Buy" rating on the stock. The consensus estimate for Tarsus Pharmaceuticals' current full-year earnings is ($0.70) per share. Lifesci Capital also issued estimates for Tarsus Pharmaceuticals' Q3 2026 earnings at ($0.21) EPS and FY2026 earnings at ($0.66) EPS.

Other analysts also recently issued reports about the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Tarsus Pharmaceuticals in a research report on Tuesday, April 21st. The Goldman Sachs Group reiterated a "neutral" rating and issued a $68.00 price objective on shares of Tarsus Pharmaceuticals in a research report on Thursday, February 5th. Guggenheim lifted their price objective on shares of Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the company a "buy" rating in a research report on Wednesday, February 25th. Wall Street Zen downgraded shares of Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, April 18th. Finally, HC Wainwright reiterated a "buy" rating and issued a $88.00 price objective on shares of Tarsus Pharmaceuticals in a research report on Monday, May 4th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $90.67.

Tarsus Pharmaceuticals Stock Performance

Shares of NASDAQ:TARS opened at $61.21 on Monday. The company has a market cap of $2.63 billion, a PE ratio of -53.69 and a beta of 0.52. The company's 50-day moving average price is $68.72 and its 200 day moving average price is $71.87. Tarsus Pharmaceuticals has a fifty-two week low of $38.51 and a fifty-two week high of $85.25. The company has a quick ratio of 3.71, a current ratio of 3.74 and a debt-to-equity ratio of 0.21.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.24. The firm had revenue of $162.05 million for the quarter, compared to the consensus estimate of $149.60 million. Tarsus Pharmaceuticals had a negative net margin of 9.02% and a negative return on equity of 14.19%.

Insider Activity at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 11,964 shares of the business's stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $67.00, for a total transaction of $801,588.00. Following the sale, the chief executive officer directly owned 33,421 shares in the company, valued at approximately $2,239,207. The trade was a 26.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Elizabeth Yeu Lin sold 390 shares of the business's stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $67.00, for a total transaction of $26,130.00. Following the sale, the insider owned 23,308 shares in the company, valued at $1,561,636. This trade represents a 1.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 79,391 shares of company stock worth $5,432,035 in the last three months. Insiders own 9.64% of the company's stock.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. TimesSquare Capital Management LLC acquired a new position in shares of Tarsus Pharmaceuticals in the 3rd quarter worth approximately $15,898,000. Jennison Associates LLC grew its stake in shares of Tarsus Pharmaceuticals by 5.5% in the 3rd quarter. Jennison Associates LLC now owns 2,604,580 shares of the company's stock worth $154,790,000 after purchasing an additional 136,582 shares during the last quarter. Citigroup Inc. grew its stake in shares of Tarsus Pharmaceuticals by 78.1% in the 3rd quarter. Citigroup Inc. now owns 40,591 shares of the company's stock worth $2,412,000 after purchasing an additional 17,797 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH increased its position in shares of Tarsus Pharmaceuticals by 77.0% in the third quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 91,590 shares of the company's stock worth $5,443,000 after acquiring an additional 39,838 shares in the last quarter. Finally, Artisan Partners Limited Partnership increased its position in shares of Tarsus Pharmaceuticals by 3.5% in the third quarter. Artisan Partners Limited Partnership now owns 558,326 shares of the company's stock worth $33,181,000 after acquiring an additional 19,023 shares in the last quarter. Institutional investors and hedge funds own 90.01% of the company's stock.

Tarsus Pharmaceuticals News Summary

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Tarsus reported Q1 EPS of -$0.16, beating expectations for a -$0.40 loss, and revenue of $162.05 million, above the $149.60 million consensus. Article Title
• Positive Sentiment: The company said Q1 XDEMVY net product sales topped $145 million, up more than 85% year over year, and reaffirmed 2026 guidance of $670 million to $700 million in XDEMVY sales. Article Title
• Neutral Sentiment: Management also highlighted broader business momentum, including stronger prescribing trends and the start of a Phase 2 Lyme disease prevention trial for TP-05. Article Title
• Neutral Sentiment: LifeSci Capital and HC Wainwright mostly kept bullish ratings on Tarsus, but several firms slightly lowered near-term EPS estimates after the report, which could temper enthusiasm. Article Title
• Negative Sentiment: Lifescis Capital cut Q1, Q2, Q3 and FY2026 EPS estimates, and HC Wainwright trimmed FY2027-FY2029 estimates slightly, reflecting continued losses in the near term despite long-term optimism. Article Title

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company's research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus's lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.